Interacciones de Upadacitinib

Additionally, concomitant use of ORENCIA with other biologic RA/PsA therapy or JAK inhibitors is not recommended. (etiqueta de Abatacept, Advertencias y precauciones)

…randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings… (etiqueta de Upadacitinib, Advertencia en recuadro)

…safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings and Precautions ( 5.2 )] . (etiqueta de Upadacitinib, Advertencia en recuadro)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

…randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings… (etiqueta de Upadacitinib, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (etiqueta de Captopril, Advertencias)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etiqueta de Cladribina, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

…safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings and Precautions ( 5.2 )] . (etiqueta de Upadacitinib, Advertencia en recuadro)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

…safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings and Precautions ( 5.2 )] . (etiqueta de Upadacitinib, Advertencia en recuadro)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Food or drink containing grapefruit should be avoided during treatment with RINVOQ/RINVOQ LQ. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

…randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings… (etiqueta de Upadacitinib, Advertencia en recuadro)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

…randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings… (etiqueta de Upadacitinib, Advertencia en recuadro)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions ( 5.3 )] . (etiqueta de Upadacitinib, Advertencia en recuadro)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etiqueta de Tacrolimus, Advertencia en recuadro)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

…randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings… (etiqueta de Upadacitinib, Advertencia en recuadro)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (etiqueta de Ácido fenofíbrico, Interacciones medicamentosas)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etiqueta de Amlodipino, Interacciones medicamentosas)

Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (etiqueta de Upadacitinib, Advertencias y precauciones)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etiqueta de Amlodipino y olmesartán, Interacciones medicamentosas)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when coadministered. (etiqueta de Amlodipino y valsartán, Interacciones medicamentosas)

Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (etiqueta de Upadacitinib, Advertencias y precauciones)

Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (etiqueta de Denosumab, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (etiqueta de Upadacitinib, Advertencias y precauciones)

Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (etiqueta de Fenofibrato, Interacciones medicamentosas)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

HBV reactivation has also been reported in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (etiqueta de Ledipasvir y sofosbuvir, Advertencias y precauciones)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (etiqueta de Leflunomida, Advertencias y precauciones)

Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (etiqueta de Mercaptopurina, Advertencias y precauciones)

Lymphoma and Other Malignancies Patients receiving immunosuppressants, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin [see Adverse Reactions ( 6.1 )]. (etiqueta de Micofenolato, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etiqueta de Olmesartán, amlodipino e hidroclorotiazida, Interacciones medicamentosas)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (etiqueta de Penicilamina, Advertencias)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (etiqueta de Upadacitinib, Advertencias y precauciones)

Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (etiqueta de Upadacitinib, Advertencias y precauciones)

Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (etiqueta de Upadacitinib, Advertencias y precauciones)

HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (etiqueta de Sofosbuvir y velpatasvir, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etiqueta de Telmisartán y amlodipino, Interacciones medicamentosas)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (etiqueta de Tinidazol, Interacciones medicamentosas)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etiqueta de Upadacitinib, Advertencias y precauciones)

Thirty-four patients were treated with corticosteroids and one patient was treated with a non-steroidal immunosuppressant. (etiqueta de Axitinib, Advertencias y precauciones)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etiqueta de Metimazol, Advertencias)

Immunosuppressive Drugs Tacrolimus: Tacrolimus has been shown to be metabolized via the CYP3A system. (etiqueta de Nifedipino, Precauciones)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etiqueta de Propiltiouracilo, Advertencias)